News

GlobalData on MSN6d
Ventyx reports positive outcomes from trial of VTX3232 for Parkinson’s
Ventyx Biosciences has reported encouraging top-line outcomes from its single-centre Phase IIa trial of the central nervous ...
PMLive4d
Ventyx’s investigational NLRP3 inhibitor shows promise in Parkinson’s disease
Ventyx Biosciences has shared promising top-line results from a phase 2a study of its investigational central nervous system ...
Investing6d
Ventyx stock steady as Parkinson’s drug shows biomarker reductions
Ventyx Biosciences Inc (NASDAQ: VTYX), currently trading at $2.20 and considered undervalued according to InvestingPro analysis, announced results Tuesday from its Phase 2a trial of VTX3232 for ...
BioSpace6d
Draig Takes Flight With $140M Series A To Advance Neuropsych Drugs
The U.K.-based biotech is set to enter mid-stage studies for its depression drug this year, while two other GABAA modulators ...
Investing6d
Ventyx stock steady as Parkinson’s drug shows biomarker reductions
Ventyx Biosciences Inc (NASDAQ: VTYX), currently trading at $2.20 and considered undervalued according to InvestingPro analysis, announced results Tuesday from its Phase 2a trial of VTX3232 for ...
PipelineReview.com6d
Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease ...
VTX3232 treatment was associated with improvement in both motor and non-motor symptoms of Parkinson’s disease, as measured by MDS-UPDRS. Statistically significant reductions in Part I (p<0.05), Part ...